Want to see TSE:RVV full AI Analyst Report?
Top Page
Revive Therapeutics
(RVV)
Select Model
Select Model
Rating:43Neutral
Price Target:
C$0.03
▲(240.00% Upside)
Action:Reiterated
Date:07/03/26
The score is primarily held down by very weak financial performance (no revenue, ongoing losses, negative equity, and continued cash burn), which raises funding/dilution risk. Technical indicators add a mildly negative bias (below key moving averages and negative MACD), while valuation provides limited support given the negative P/E and lack of dividend yield.
Positive Factors
Low Absolute Leverage
Very low reported debt in absolute terms reduces interest burden and bankruptcy risk for a development-stage biotech. Over 2-6 months this preserves optionality to fund R&D from equity or partnerships rather than servicing debt, aiding strategic flexibility.
Negative Factors
Pre-revenue Profile
No commercialization means the business lacks a sustainable revenue base to absorb R&D and G&A costs. Over the medium term the company remains reliant on external capital to fund operations, increasing execution risk if fundraising conditions tighten or clinical programs delay.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Absolute Leverage
Very low reported debt in absolute terms reduces interest burden and bankruptcy risk for a development-stage biotech. Over 2-6 months this preserves optionality to fund R&D from equity or partnerships rather than servicing debt, aiding strategic flexibility.
Read all positive factors
Revive Therapeutics (RVV) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$12.56M
Dividend YieldN/A
Average Volume (3M)285.50K
Price to Earnings (P/E)―
Beta (1Y)-1.47
Revenue GrowthN/A
EPS Growth-162.50%
CountryCA
Employees2
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding418,564,270
10 Day Avg. Volume295,136
30 Day Avg. Volume285,498
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.43
Price to Sales (P/S)0.00
P/FCF Ratio-10.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Revive Therapeutics Business Overview & Revenue Model
Company Description
Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammato...
How the Company Makes Money
null...
Revive Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -203.00 | -248.00 | -328.00 | -434.00 | -578.00 | -775.00 |
| EBITDA | -10.66M | -11.01M | -5.60M | -5.52M | -17.74M | -18.57M |
| Net Income | -10.62M | -11.01M | -5.62M | -6.32M | -17.83M | -20.20M |
Balance Sheet | ||||||
| Total Assets | 281.77K | 205.02K | 10.64M | 14.25M | 17.07M | 29.81M |
| Cash, Cash Equivalents and Short-Term Investments | 22.66K | 24.56K | 773.07K | 2.09M | 3.92M | 16.60M |
| Total Debt | 70.77K | 66.87K | 25.22K | 219.69K | 327.73K | 415.84K |
| Total Liabilities | 4.31M | 3.66M | 3.40M | 3.60M | 4.46M | 999.68K |
| Stockholders Equity | -4.02M | -3.46M | 7.23M | 10.65M | 12.60M | 28.81M |
Cash Flow | ||||||
| Free Cash Flow | -156.71K | -807.66K | -3.29M | -6.03M | -13.06M | -11.31M |
| Operating Cash Flow | -156.71K | -807.66K | -3.29M | -6.03M | -13.06M | -8.31M |
| Investing Cash Flow | 0.00 | -30.00K | 0.00 | 0.00 | 0.00 | -2.72M |
| Financing Cash Flow | 122.95K | 39.15K | 1.98M | 4.20M | 376.35K | 26.24M |
Revive Therapeutics Technical Analysis
Negative
0.01
Price Trends
0.03
Negative
0.03
Negative
0.02
Positive
Market Momentum
>-0.01
Negative
48.41
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RVV, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.41 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RVV.
Revive Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$28.19M | -3.85 | -461.32% | ― | 83.87% | -72.88% | |
44 Neutral | C$11.16M | -2.39 | ― | ― | -25.05% | 67.74% | |
43 Neutral | C$12.56M | -1.31 | 899.59% | ― | ― | -162.50% | |
40 Underperform | C$1.19M | -0.14 | -82.37% | ― | -53.86% | 36.41% |
* Healthcare Sector Average
TSE:RVV
Revive Therapeutics
0.03
<0.01
50.00%
TSE:MVMD
Mountain Valley MD
0.08
0.06
300.00%
TSE:PCLO
PharmaCielo
0.06
0.02
40.00%
TSE:RAMM
Ramm Pharma
0.01
0.00
0.00%
Revive Therapeutics Corporate Events
Regulatory Filings and Compliance
BlackRock Disclosure Confirms Significant Stake in Caledonia Mining
Positive
Jul 16, 2026
Caledonia Mining said it has been notified by BlackRock, Inc. that the asset manager has crossed a regulatory threshold in its holding of the miner’s shares. As of July 14, BlackRock holds 5.00% of Caledonia’s voting rights through sha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.